A Phase 4 interventional study of Tranexamic Acid in Hemoptysis, sponsored by Dow University of Health Sciences. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Dow University of Health Sciences · Phase 4, Interventional, and Treatment
This will be a prospective comparative cohort study and will take place at the Ward II- Ojha Institute of Chest Diseases (OICD) ,Dow University of Health Sciences in Karachi.
It will be conducted over six months after obtaining necessary approvals. We will recruit 154 patients aged 18-60 years, regardless of gender, who will present with complain of hemoptysis. Patients will be selected through a non-probability consecutive sampling method, where each eligible patient will be approached for participation.
Participants will be randomly assigned to one of two groups using a lottery method:
Once patients give consent for participation, we will gather detailed medical history. Blood tests and X-rays will be done to assess each patient's health status.
We will then monitor the amount of blood expectorated after 30 minutes, 6 hours, 12 hours, and 24 hours post-administration. We will also observe any side effects from the treatment.
Exclusion Criteria:
Drug: Tranexamic Acid
Drug: Tranexamic Acid
Tranexamic acid 500 mg administered via inhaled route three times daily or intravenous route three times daily for management of hemoptysis
Significant reduction in hemoptysis
Proportion of patients achieving more than 50% reduction in hemoptysis blood volume after administration of Tranexamic Acid.
Time frame: 2 hours after drug administration
Amount of hemoptysis reduction
Change in amount of blood loss due to hemoptysis after treatment.
Time frame: 30 minutes, 6 hours, 12 hours, and 24 hours after drug administration
Side effects of Tranexamic Acid
Presence of adverse effects after administration of Tranexamic Acid, including redness, burning, pain, swelling, or other reported side effects.
Time frame: Within 24 hours after drug administration
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dow University of Health Sciences